Bioconjugates, ADCs & Chemistry - Abzena

Bioconjugates, ADCs & Chemistry

Accelerate your timeline to the clinic or the market with our expertise in complex chemistry and bioconjugation services.

We are moving bioconjugates forward.

14+ conjugates in clinic including radiolabeled, oncology, and oligonucleotides.

2000+ conjugates developed for critical assays, and lead candidate selections.

50+ bioconjugation programs scaled up to produce multi gram batches.

Abzena are a leading, fully integrated bioconjugates & ADCs CDMO. We offer expert development and manufacturing services, and end-to-end solutions including our advanced ThioBridge™ ADC development platform.
Our bioconjugation process development group is purpose built for the optimization and scale-up of your ADCs and bioconjugates.

Bioconjugates & Antibody-Drug Conjugates (ADCs) offer a complex development and manufacturing challenge. Abzena’s experience in bioconjugation services, having produced over 400 ADCs, and complete end to end solution simplifies the development process, and accelerates timelines to reach the clinic or market. Our specialized services for bioconjugates & ADCs provide:

  • Early de-risking & optimization
  • Process development & optimization
  • Formulation development
  • Analytical method development
  • Linker payload design & synthesis
  • Clinical to commercial manufacture

Specialized Bioconjugation Services

The Abzena ADC Toolbox

Building on the unmatched expertise of our scientists, the IP we’ve generated, and our advanced facilities in the UK and US, we have everything you need to implement fully integrated commercial bioconjugation & ADC development and manufacturing programs.

Small Molecule Intermediates

We design and deliver tailored solutions for small molecule intermediates including high potency chemistrylinker payloads, payload-linker chemical intermediates, bioconjugation and antibody-drug conjugates (ADCs). We support partners with the design, synthesis and manufacture of payloads and payload-linker constructs for ADC and bioconjugation.

Leveraging our experience in the synthesis of payloads, linkers, and payload-linker chemical intermediate constructs we enable rapid generation of structure activity relationships (SAR) of various linker combinations with your new payloads. We identify the most suitable linker for your ADC profile.

Bioconjugates & Chemistry Services

Moving medicines created with ADCs, bioconjugates and linker payloads forward is where we excel. Abzena is the leading, fully integrated, bioconjugate contract development and manufacturing services provider through to commercialization. We offer access to genuine scientific experts, streamlined development solutions, interconnected teams and full end-to-end support – all under one organization.

De-risking bioconjugate & ADC development

Through a comprehensive technology transfer process, we deliver a successful scale-up model to ensure robust and consistent manufacturing process from clinical to commercial scale.

 

We collaborate with your team to de-risk the pathway to commercialization, ensure manufacturability, and deliver a quality medicine to the patient.

 

Our capabilities include:

  • Sartorius Sartoflow® Smart and Advance TFF systems for scale-up development and production in process development at volumes from 100mL – 50L and 0.1 – 2.1 m2 membrane surface area allowing for straightforward transfer to cGMP manufacturing
  • Sartorius Sartoflow® Alpha Plus SU and FlexAct® SU TFF systems for GMP manufacturing with volume ranges from 1 – 200L and up to 3.5 m2 membrane surface area
  • Full complement of AKTA FPLC™ systems in process development including an AKTA Pilot FPLC skid in process development capable of batch purification of more than 250g of bioconjugates in a day
  • AKTA Ready Gradient chromatography skid in GMP manufacturing suite capable of batch purification of greater than 1kg bioconjugate in a day
  • Conjugation reaction stirring capabilities include rocking motion mixers of volumes up to 50L and Sartorius LevMixer® pallet tanks from 50 – 1000L volume capacity

Our bioconjugation processes

Our conjugation processes are developed and transferred to our cGMP manufacturing team minimizing challenges seen during process transfers. We develop the most effective processes for manufacturing at toxicology, clinical, and commercial scale using quality by design (QbD) principles.

Our knowledge of cGMP manufacturing enables us to successfully transfer existing processes into our facilities or develop a new innovative process, when needed, to meet your program needs.

Our processes follow ICH Product Lifecycle guidelines which ensure a robust and well characterized scalable manufacturing process.

Utilizing analytics, we ensure the right product quality attributes for your program.

ThioBridge™: ADC Development Platform

We continue to pursue advances in technology, processes and knowledge to keep ourselves and our customers at the forefront of innovation. Our agility and dedication mean we can streamline your program and mitigate project risk while producing groundbreaking treatments.

Our unique ThioBridge™ conjugation technology has been proven to enhance ADC development by overcoming issues with existing technologies in order to improve stability, potency, and efficacy. If you are looking to rapidly move your ADC program to its next regulatory or clinical milestone, access our latest information on ThioBridge™ today to learn how.